PROFIT试验:中度大分割放疗与常规分割放疗在前列腺癌患者报告生活质量上的比较
PROFIT是一项3期随机临床试验,纳入1206例中危前列腺癌患者,比较中度大分割放疗(HF,60 Gy/20次/4周)与常规分割放疗(CF,78 Gy/39次/8周)。患者报告结局显示两组在泌尿、肠道、性功能和激素领域及总体健康相关生活质量上无显著差异,仅48个月时肠道子领域的最小重要差异比例 favoring HF。结论支持中度HF作为中危前列腺癌的标准治疗。
要点
- 两组患者报告结局在泌尿、肠道、性功能和激素领域均无显著差异。
- 48个月时肠道汇总评分和功能评分的最小重要差异比例显著 favoring HF。
- 两组治疗满意度均高,≥88%患者满意或非常满意。
核心结论
- PROFIT试验患者报告结局显示CF与HF放疗方案在泌尿、肠道、性功能、激素及总体健康相关生活质量上无显著差异。
- 该研究提供1级证据支持中度HF放疗作为中危前列腺癌的标准治疗。
研究设计与样本
- PROFIT为3期随机临床试验,纳入1206例中危前列腺癌患者,来自加拿大14个中心、澳大利亚12个中心和法国1个中心。
- 患者随机接受CF(78 Gy/39次/8周)或HF(60 Gy/20次/4周)放疗。
- 患者报告结局在基线、24和48个月时采用EPIC、AUASS和SF-12(含PCS和MCS)评估。
- 最小重要差异定义为各时间点领域或子领域健康相关生活质量评分较基线下降≥0.5倍标准差。
- 统计显著性设定为p < 0.01。
主要发现
- AUASS结果两组相似且随时间稳定(中位数5分,四分位距2-9;p > 0.2)。
- 两组在任何时间点的泌尿、肠道、性功能和激素领域及子领域评分均无显著差异(p > 0.02)。
- 性功能领域随时间下降最大,两组从基线至24个月均下降≥10分。
- SF-12的PCS和MCS平均评分两组相似且各时间点保持稳定。
- 48个月时肠道子领域报告最小重要差异的患者比例有显著差异,HF组肠道汇总评分(53% vs 44%;p = 0.01)和肠道功能评分(51% vs 39%;p = 0.001)的最小重要差异比例显著更低。
关键数值与推荐
- CF方案:78 Gy分39次,8周完成;HF方案:60 Gy分20次,4周完成。
- 最小重要差异阈值:领域或子领域评分较基线下降≥0.5倍标准差。
- 统计显著性阈值:p < 0.01。
- 48个月肠道汇总评分最小重要差异比例:HF组53% vs CF组44%(p = 0.01)。
- 48个月肠道功能评分最小重要差异比例:HF组51% vs CF组39%(p = 0.001)。
临床怎么用
- 中度大分割放疗(60 Gy/20次/4周)可作为中危前列腺癌的标准治疗选择,患者报告的生活质量与常规分割放疗相当。
- 临床决策时可告知患者两种方案在泌尿、肠道、性功能和激素相关生活质量上长期无显著差异。
- HF方案在48个月时肠道相关生活质量的最小重要差异比例更低,可能对肠道功能保护有优势。
局限性
- 原文摘要未明确报告本研究的具体局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The PROFIT trial was designed to compare moderately hypofractionated (HF) radiotherapy versus conventional fractionation (CF) for patients with intermediate-risk prostate cancer (IR-PC). Similar efficacy and toxicity outcomes were previously reported. The aim of the current analysis was to evaluate differences in long-term patient-reported outcomes (PROs) between the HF and CF arms in PROFIT. METHODS: For the PROFIT phase 3 randomized clinical trial, patients with IR-PC (n = 1206) were enrolled from 14 sites in Canada, 12 in Australia, and one in France and randomized to receive 78 Gy in 39 fractions over 8 wk (CF) or 60 Gy in 20 fractions over 4 wk (HF). PROs were evaluated at baseline and 24 and 48 mo using the Expanded Prostate Cancer Index Composite, American Urological Association Symptom Score (AUASS), and the 12-item Short Form Health Survey (SF-12) comprising a physical component summary (PCS) and a mental component summary (MCS). A minimally important difference (MID) was defined as a deterioration in domain- or subdomain-specific health-related quality of life (HRQoL) score by ≥0.5 times the standard deviation at each time point in comparison to baseline. Statistical significance was set at p < 0.01. KEY FINDINGS AND LIMITATIONS: AUASS results were similar and stable over time in both arms (median 5 points, interquartile range 2-9; p > 0.2). There were no significant differences in scores for urinary, bowel, sexual, and hormonal domains or subdomains between the arms at any time point (p > 0.02). The greatest decline over time occurred in sexual domain, with a decrease of ≥10 points from baseline to 24 mo in both arms. SF-12 mean scores for both PSC and MSC were similar in the two arms and remained stable at all time points. The only significant differences in the proportion of patients reporting MIDs were for the bowel subdomains at 48 mo, with significant MID reductions favoring HF for both the bowel summary score (53% vs 44%; p = 0.01) and bowel function score (51% vs 39%; p = 0.001). Overall treatment satisfaction was high in both arms: ≥88% of patients were either satisfied or extremely satisfied with their treatment. CONCLUSIONS AND CLINICAL IMPLICATIONS: PRO results from the PROFIT trial suggest no significant differences in urinary, bowel, sexual, hormonal, and general HRQoL between CF and HF radiotherapy schedules. This study provides level 1 evidence supporting the use of moderate HF radiotherapy as standard treatment in patients with IR-PC. This trial is registered on ClinicalTrials.gov as NCT00304759.
引用
- Sanmamed N, Dayes I, Catton C, et al. Patient-reported Quality of Life in PROFIT, a Phase 3 Randomized Clinical Trial Evaluating Moderately Hypofractionated Radiotherapy for Intermediate-risk Prostate Cancer. Eur Urol Oncol. 2025. PMID: 40335398. doi:10.1016/j.euo.2025.03.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。